康龙化成（300759）(03759)公布，公司近日接到公司实际控制人之一楼小强先生的函告，获悉楼小强 先生将其所持有的公司部分股份进行了质押和解除质押。 2025年9月25日，楼小强质押1200万股股份，解除质押1515万股股份。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 康龙化成（北京）新药技术股份有限公司 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年9月29日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-053 截 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002622 | 皓宸医疗 | 3.21 | -6.96% | 91.76万 | 2.95 Z | | 603127 | 昭衍新药 | 35.31 | -4.39% | 32.87万 | 11.51亿 | | 688046 | 药康生物 | 17.66 | -4.13% | 3.39万 | 6034.58万 | | 688131 | 皓元医药 | 77.66 | -1.97% | 4.39万 | 3.40亿 | | 000504 | *ST生物 | 9.16 | -1.72% | 2.36万 | 2169.47万 | | 835670 | 数字人 | 15.37 | -1.54% | 2.52万 | 3907.47万 | | 688073 | 毕得医药 | 75.92 | -1.27% | 8913.84 | 6690.90万 | | 688710 | 益诺恩 | 46.80 | -1.24% | 9044.18 | 4239.32万 | | 60 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-053 康龙化成（北京）新药技术股份有限公司 关于公司实际控制人股份质押和解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押及解除质押的基本情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）近日接到公 司实际控制人之一楼小强先生的函告，获悉楼小强先生将其所持有的公司部分股 份进行了质押和解除质押，具体情况如下： 上述质押股份不负担重大资产重组等业绩补偿义务，对公司的生产经营、公 司治理不会产生重大影响，实际控制人亦将积极防范风险。 股东名 称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质 押股份数量 （股） 占其所 持股份 比例 占公司 总股本 比例 起始日 解除日期 质权人 楼小强 实际控制人 之一 13,150,000 21.72% 0.74% 2025 年 5 月 29 日 2025 年 9 月 26 日 华泰证券（上 海）资产管理 2,000,000 3.30% 0.11% 有限公司 2025 年 5 月 29 日 2025 年 9 ...

人民财讯9月29日电，有投资者在互动平台向康龙化成（300759）提问，美国自10月1日开始对药品加征 100%关税，请问对贵公司经营是否有影响？康龙化成回复称，截至目前，美国加征关税对公司业务产 生的影响有限。目前公司并未收到客户或其他合作伙伴向公司反馈关税问题对业务合作造成影响。对于 宏观的不确定性风险，公司会密切关注相关政策动向。地缘政治背景下，也敬请投资者注意投资风险。 ...

Summary of Conference Call Records Industry Overview - The conference call primarily discusses the **biotechnology and pharmaceutical contract development and manufacturing organization (CDMO)** industry, focusing on companies like **WuXi AppTec**, **Kailai Ying**, and **Boteng** [1][2]. Key Points and Arguments 1. **Order Growth and Capacity Utilization** - WuXi AppTec and Kailai Ying accelerated overseas MNC orders in Q3, leading to increased capacity utilization. Small molecule oral drug orders began to materialize in Q3, expected to contribute to revenue in Q4 and increase gradually next year [1][2]. 2. **Emerging Business Performance** - Kailai Ying's emerging business is nearly at full capacity, particularly in its Tianjin factory, with recent price increases. Boteng's traditional small molecule business also raised prices by approximately 8-10% due to improved capacity utilization, primarily targeting biotech clients [1][5]. 3. **Biosimilar Exemption Benefits** - The exemption for Phase III biosimilars is a significant positive for the large molecule CDMO sector, expected to accelerate overseas orders in Q4 or the first half of next year, positively impacting media and large molecule CGM [1][6]. 4. **Domestic CRO Demand Surge** - Domestic CRO companies saw a further increase in demand in Q3, particularly in pharmacodynamics and toxicology. In vitro pharmacodynamics orders showed a year-on-year growth of 20-30% in H1, reaching 35-40% in Q3, with expectations for continued growth into H1 2026 [1][7][8]. 5. **Biotech Industry Budget Management** - The biotech industry's budget management in 2025 is more relaxed compared to 2024, with reduced pressure on order discounts and price negotiations, leading to an anticipated increase in biotech order prices [1][9]. 6. **Price Trends for Experimental Monkeys** - The price of experimental monkeys increased significantly in Q3, averaging around 95,000 yuan in H1, rising to 110,000-120,000 yuan by late August, reflecting increased demand [1][10]. 7. **Clinical Sector Performance** - The clinical sector saw a 5% growth in total volume in Q3 compared to Q2. Although prices have not yet increased, there is potential for industry-wide price hikes in Q4 due to rising demand and relaxed budgets [1][11]. 8. **Competitive Strategies in Clinical Sector** - Major companies in the clinical sector are adjusting their competitive strategies. For instance, companies like Kailai Ying and KunTuo are focusing on high-margin orders and reducing participation in price wars, which may support future price increases [1][12]. 9. **Impact of External Factors** - The influence of external factors, such as Trump's tweets, on CDMO businesses like WuXi AppTec is limited, as these companies have already engaged with U.S. counterparts regarding capacity issues [1][13][14]. Additional Important Insights - The overall sentiment in the industry is optimistic, with expectations for continued growth in orders and potential price increases across various segments, driven by improved demand and strategic adjustments by key players [1][2][9].

Market Overview - The Hang Seng Index closed at 26,128.2 points, down 1.57% for the week, while the Hang Seng Tech Index fell 1.58% to 6,195.11 points, and the National Enterprises Index decreased by 1.79% to 9,303.10 points [1] Fund Flow - The net inflow for the Hong Kong Stock Connect (Shanghai to Hong Kong) over the past 5 days was +23.253 billion, and for the Shenzhen to Hong Kong was +20.706 billion. Over the past 20 days, the inflow was +72.618 billion and +102.073 billion respectively. For the past 60 days, the inflow reached +182.005 billion and +231.819 billion [4] Alibaba's Performance - Alibaba's stock rose 4.65% to HKD 166.50, with a notable single-day increase of 9.16% on September 24. This performance was driven by positive signals from the 2025 Alibaba Cloud Summit, where the CEO announced an increased investment in AI infrastructure and a goal to enhance data center energy efficiency by tenfold by 2032. The company also introduced its new AI model Qwen3-Max, which performed well in global evaluations [5] Pharmaceutical Sector - The pharmaceutical sector experienced a downturn, with Fosun Pharma dropping 11.19%. Other companies like Kanglong Chemical and 3SBio also saw declines. The primary reasons for this adjustment were overseas policy disturbances, including fluctuating expectations of interest rate cuts by the Federal Reserve and proposed tariffs on pharmaceutical products by Trump. However, the actual impact on Chinese innovative pharmaceutical companies is expected to be limited due to their licensing models [6] New Energy Sector - The new energy sector showed strong performance, with Zhongxin New Energy rising 15.36% to HKD 30.94, marking over 140% increase year-to-date. This growth is attributed to robust performance in the company's energy storage business and positive institutional evaluations. Policy support from the government, including tax incentives and technological advancements, is expected to foster further growth in the sector [7] Online Travel Industry - The online travel sector is witnessing a transformation, with cross-province travel orders increasing by 45% year-on-year during the "Golden Week." Companies are shifting from price competition to AI-driven value creation, enhancing user experience through AI applications. Major platforms are integrating AI into their services, indicating a shift in competitive dynamics from resource monopolization to technological service capabilities [8] U.S. Market Signals - The U.S. bond market is showing concerning signals, with investment-grade corporate bond risk premiums at a 27-year low and signs of rising consumer defaults. These trends echo pre-2007 financial crisis characteristics. Additionally, the Trump administration's trade protectionist policies are reshaping global trade dynamics, with tariffs on various products potentially leading to a restructuring of global supply chains [9]

Core Viewpoint - Kanglong Chemical is recognized as a leading global drug research and development enterprise with a full-process, integrated, international, and multi-therapy approach [1] Company Summary - The company’s laboratory services, small molecule CDMO, clinical CRO, and large molecule and cell gene therapy services are expected to have ample growth momentum and broad growth space [1] - Kanglong Chemical is on a path to becoming a global integrated research and production service giant [1] Industry Summary - Given the growth prospects of the company and the global competitive advantages of China's CXO industry, a higher valuation level is deemed appropriate [1] - The report suggests a target price of 47.73 yuan based on a 40 times PE for 2026, and a target price of 39.34 Hong Kong dollars based on a 30 times PE for 2026 [1] - The report initiates coverage with a "recommend" rating [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年9月26日 证券代码：300759 证券简称：康龙化成 公告编号：2025-052 康龙化成（北京）新药技术股份有限公司 关于参与私募股权投资基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、投资事项概述 为 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-052 康龙化成（北京）新药技术股份有限公司 三、对公司的影响 德诚二期基金适度延长投资期将使基金有更充分的时间和灵活性，以应对市 场变化，发掘并执行更具价值的投资机会，从而更好地实现基金的投资目标，本 次延长投资期不会使公司产生额外的管理费，不存在损害公司和全体股东利益的 情形。除上述事项外，合伙协议的主要条款和此前披露的内容基本一致。在德诚 二期基金延长投资期后，可能存在项目实施、风险管控、投资收益的不确定性以 及退出等多方面风险因素。公司将根据该事项的进展情况依据相关法律法规履行 相应的决策程序并及时进行信息披露。 特此公告。 康龙化成（北京）新药技术股份有限公司董事会 关于参与私募股权投资基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、投资事项概述 为充分运用专业投资机构在行业内项目收集、研判的能力，提高康龙化成（北 京）新药技术股份有限公司（以下简称"公司"）投资能力，公司作为有限合伙 人以自有资金认缴出资 5,000 万元人民币参与投资宁波德诚医健投资管理合伙企 业 ...